Drug intelligence / Profile preview

A006 DPI

Development stage: Unknown
Lead developer: Amphastar Pharmaceuticals
Modality: Small Molecules
Administration: Inhalation

Overview

A006 DPI is an investigational dry powder inhaler (DPI) formulation of albuterol (salbutamol) being developed by Amphastar Pharmaceuticals. Albuterol is a short-acting beta-2 adrenergic agonist (SABA) that acts as a bronchodilator by stimulating beta-2 adrenergic receptors in the lungs, leading to the relaxation of bronchial smooth muscle and improved airflow. This formulation is primarily intended for the treatment of asthma and chronic obstructive pulmonary disease (COPD). A006 DPI has been evaluated in multiple Phase 2 clinical trials to assess its pharmacokinetics, safety, and efficacy, often using Proventil HFA (albuterol metered-dose inhaler) as an active comparator.

Other names: Albuterol DPISalbutamol DPI

Targets

ADRB2 (β2)

Beyond the preview

Go deeper on A006 DPI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A006 DPI.

Explore the full profile